60 phenotypes from 4 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Sptbn1tm1.1Mnr/Sptbn1tm1.1Mnr Tg(Nes-cre)1Kln/0 involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL	abnormal axon initial segment morphology	J:186168
	postnatal lethality, incomplete penetrance	J:186168
Sptbn1tm1a(EUCOMM)Wtsi/Sptbn1+ B6JTyr;B6N-Sptbn1tm1a(EUCOMM)Wtsi/Wtsi	decreased body weight	J:175295
	decreased circulating alanine transaminase level	J:175295
	decreased circulating cholesterol level	J:175295
	decreased circulating HDL cholesterol level	J:175295
	decreased circulating LDL cholesterol level	J:175295
	decreased circulating serum albumin level	J:175295
	decreased circulating total protein level	J:175295
	decreased lactate dehydrogenase level	J:175295
Sptbn1tm1a(EUCOMM)Wtsi/Sptbn1tm1a(EUCOMM)Wtsi involves: C57BL/6N	abnormal fetal cardiomyocyte morphology	J:219548
	abnormal heart development	J:219548
	abnormal heart ventricle wall thickness	J:219548
	absent coronary vessels	J:219548
	decreased fetal cardiomyocyte proliferation	J:219548
	decreased mitotic index	J:219548
	edema	J:200082
	hemorrhage	J:200082
	increased fetal cardiomyocyte apoptosis	J:219548
	myocardial trabeculae hypoplasia	J:219548
	small heart	J:219548
	thin left ventricle myocardium compact layer	J:219548
	ventricular septal defect	J:219548
Sptbn1tm1c(EUCOMM)Wtsi/Sptbn1tm1c(EUCOMM)Wtsi involves: C57BL/6J * C57BL/6N	abnormal cell cycle	J:219548
	abnormal cell cycle checkpoint function	J:219548
	abnormal fetal cardiomyocyte morphology	J:219548
	abnormal fetal cardiomyocyte physiology	J:219548
	decreased fetal cardiomyocyte proliferation	J:219548
	increased fetal cardiomyocyte apoptosis	J:219548
Sptbn1tm1Mish/Sptbn1+ involves: 129S6/SvEvTac	abnormal liver morphology	J:166879
	abnormal outer ear morphology	J:166879
	adrenal gland cyst	J:166879
	alopecia	J:166879
	enlarged heart	J:166879
	enlarged kidney	J:166879
	enlarged testis	J:166879
	increased adenoma incidence	J:166879
	increased adrenal cortical tumor incidence	J:166879
	increased body size	J:166879
	increased carcinoma incidence	J:166879
	increased glioma incidence	J:166879
	increased hepatocellular carcinoma incidence	J:166879
	increased liver tumor incidence	J:166879
	increased lung adenocarcinoma incidence	J:166879
	increased lymphoma incidence	J:166879
	increased ovary tumor incidence	J:166879
	increased renal carcinoma incidence	J:166879
	increased sarcoma incidence	J:166879
	increased testis tumor incidence	J:166879
	increased thyroid carcinoma incidence	J:166879
	increased tongue size	J:166879
	premature death	J:166879
	visceromegaly	J:166879
Sptbn1tm1Mish/Sptbn1+ involves: 129S6/SvEvTac * C57BL/6	decreased hepatocyte proliferation	J:132133
	increased hepatocellular carcinoma incidence	J:132133
Sptbn1tm1Mish/Sptbn1tm1Mish either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss)	abnormal brain development	J:81747
	abnormal craniofacial morphology	J:81747
	abnormal digestive system morphology	J:81747
	abnormal heart ventricle morphology	J:81747
	abnormal liver morphology	J:81747
	abnormal myocardial fiber morphology	J:81747
	abnormal vitelline vasculature morphology	J:81747
	decreased embryo size	J:81747
	lethality throughout fetal growth and development, complete penetrance	J:81747
	liver hypoplasia	J:81747